Skip to main content
. 2007 Dec 26;15(3):549–561. doi: 10.1128/CVI.00351-07

FIG. 3.

FIG. 3.

Cross-reactions of MAbs generated against the DENV-2 NS1 glycoprotein with overlapping synthetic peptides sequentially spanning the domain III sequence of the DENV-2 E glycoprotein. MAbs generated against either the DENV-2 NS1 (MAb 1H7.4, 5H4.3, 3D1.4, 1G5.3, 1G5.4-A1.C3, and 1C6.3) or E [control MAb 2C5.1 (C)] glycoprotein were diluted to 100 times their reciprocal log10t50 ELISA titer against the purified DENV-2 NS1 glycoprotein or DENV-2 particles (MAb 2C5.1, MAb 1H7.4 [314 ng/ml], 5H4.3 [1,714 ng/ml], 3D1.4 [442 ng/ml], MAb 1G5.3 [575 ng/ml], MAb 1G5.4-A1-C3 [1,595 ng/ml], MAb 1C6.3 [4,439 ng/ml], and MAb 2C5.1 [1,137 ng/ml]) and then incubated with duplicate sets of 47 overlapping synthetic peptides sequentially spanning the domain III (amino acids 301 to 401) sequence of the DENV-2 E glycoprotein. The average ELISA reaction (A492) against each pair of peptides is shown. Standard deviations ranged from 0.00 to 0.02.